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glaucoma screening in China: a decision-analytic Markov 
model
Jianjun Tang, Yuanbo Liang, Ciaran O’Neill, Frank Kee, Junhong Jiang, Nathan Congdon
Summary
Background Glaucoma, particularly primary angle closure glaucoma (PACG), is a leading cause of global blindness. 
Nearly half of all people with PACG are of Chinese descent. Population-level glaucoma screening has generally not 
been found to be cost-effective in high-income countries; however, this assessment has rarely been done in low-
income or middle-income countries. We aimed to assess the cost-effectiveness and cost-utility of population-level 
glaucoma screening in China.
Methods We developed decision-analytic Markov models for separate and combined screening for PACG and primary 
open angle glaucoma (POAG) to evaluate costs and benefits of community-level screening versus opportunistic case 
finding from a societal perspective. A cohort of individuals was followed in the model from age 50 years through a 
total of 30 1-year Markov cycles. Analyses were done separately for rural and urban settings. We did a meta-analysis of 
glaucoma prevalence studies in China to obtain prevalence estimates for PACG and POAG. Screening costs were 
taken from a Chinese screening programme and treatment costs from a tertiary Chinese eye hospital. Main outcomes 
were incremental cost-utility ratios (ICURs) using quality-adjusted life-years and incremental cost-effectiveness ratios 
(ICERs) using years of blindness avoided. We did one-way deterministic and simulated probabilistic sensitivity 
analyses to reflect uncertainty around ICURs and ICERs.
Findings Compared with no screening, combined screening of POAG and PACG in rural China is predicted to result 
in an ICUR of US$569 (95% CI 17 to 4180) and an ICER of $1280 (−58 to 7940), both of which are below the WHO 
cost-effectiveness threshold of one to three times rural gross domestic product. For the urban China setting, combined 
screening is predicted to result in fewer net costs and greater gain in health benefits than no screening. Findings were 
robust in all sensitivity analyses. Over 30 years, a total of 246 (95% CI 63 to 628) and 1325 (510 to 2828) years of 
blindness are predicted to be avoided for every 100 000 rural and urban residents screened, respectively.
Interpretation Population screening for glaucoma (POAG and PACG combined) is likely to be cost-effective in both 
urban and rural China. Future studies should investigate the effectiveness of interventions to improve acceptance of 
definitive care among people screened.
Funding Ulverscroft Foundation, Wenzhou Medical University Research Fund, Zhejiang Province Health Innovation 
Talents Project, and Wenzhou’s Ten Major Livelihood Issues 2015.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Glaucoma is a leading cause of global blindness, affecting 
64·3 million people worldwide in 2013, of whom a sixth 
dwell in China.1,2 Nearly half of all people with primary 
angle closure (PAC) glaucoma (PACG) are of Chinese 
descent.3 Although glaucoma can progress to blindness, 
it is generally asymptomatic in its early stages, when 
treat ment is most effective. This makes early detec­
tion crucial to reduce the risks of visual impairment.4 
Screening programmes might be of particular value in 
rural settings, where population studies suggest that less 
than 50% of cases of PACG and less than 10% of cases of 
primary open angle glaucoma (POAG) are diagnosed.5 
Among those who are diagnosed, glaucoma has already 
caused severe damage in the majority.6 However, several 
studies have reported that population­based glaucoma 
screening programmes are not cost­effective in high­
income countries such as the UK7,8 and Finland.9
We believe that glaucoma screening might be cost­
effective in a Chinese setting for two reasons. First, when 
compared with other ethnic groups, people of Chinese 
descent have a two to four times higher prevalence of 
PACG.10 The risk of blindness at diagnosis is up to 
four times higher for PACG than for POAG, which is 
the more common type of glaucoma among those of 
European descent.11 Second, screening is likely to be less 
expensive in China, due in large part to lower labour 
costs as compared with high­income countries.12
To the best of our knowledge, no studies have investigated 
whether population­based glaucoma screening is cost­
effective in China. The only cost­effectiveness study13 of 
glaucoma screening in an Asian population found that 
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screening is highly cost­effective in India. However, a 
one­time decision analysis was used, which failed to 
capture the complexity of glaucoma progression in a 
temporally explicit fashion, and applicability of this result 
to the population of China is clearly uncertain due to 
differences in disease profile and health­care systems in 
the two countries.
To fill this evidence gap, we aim to provide evidence­
based policy recommendations by building a compre­
hensive and dynamic decision­analytic Markov model 
incorporating the transition between various disease 
stages across time and providing for a robust estimate 
of the cost­effectiveness of population screening for 
glaucoma in China. This model is informed by a large 
number of glaucoma prevalence studies done in China 
and includes screening and treatment costs obtained from 
an actual glaucoma screening programme and a tertiary 
referral eye hospital in China. For illustrative purposes, we 
analysed rural and urban settings separately because they 
are expected to differ in terms of glaucoma prevalence14,15 
and access to and compliance16 with health treatments.
Methods
Model overview
TreeAge Pro (TreeAge Software; Williamstown, MA, 
USA) was used to build Markov models monitoring the 
transition between discrete health states and the effects 
of prescribed interventions on transition probabilities. 
Three Markov models were built to describe separate 
screening for PACG and POAG and simultaneous 
screening for both conditions together (appendix). The 
latter is the most likely screening scenario but we felt it 
would be useful to understand the separate effects of 
the two diseases on combined screening, as approaches 
to screening differ somewhat. Analysing the two disease 
processes separately provides additional information 
potentially relevant to other low­resource settings where 
only one condition (such as POAG for African and Africa­
derived populations) prevails. However, we acknowledge 
that there are additional benefits that arise as a result of 
screening both diseases; therefore, there might be some 
underestimation of cost­effectiveness in the separate 
screening scenarios.
A cohort of individuals was followed in the model from 
age 50 years through a total of 30 1­year Markov cycles.17 
Individuals were allowed to enter as healthy (free from 
glaucoma) or unhealthy (affected by glaucoma) and could 
transition to death from any health state. The Markov 
model for POAG was based on the International Society 
of Geographical and Epidemiologic Ophthalmology 
(ISGEO) glaucoma classification, which comprises 
five stages in addition to normal vision: mild POAG, 
moderate POAG, severe POAG, POAG­related unilateral 
blindness, and POAG­related bilateral blindness.18 Each 
stage has a probability of progression to the next stage, 
but due to the nature of the disease, the model does not 
permit regression to an earlier stage even with treatment. 
The ISGEO classi fication of PACG was used, also 
Research in context
Evidence before this study
PubMed, MEDLINE, CNKI, and Embase were searched for 
cost-effectiveness studies of glaucoma screening published 
in English or Chinese up to Oct 1, 2018, using the terms 
“glaucoma” AND “screening” OR “detection” AND “economic 
modelling” OR “cost-effectiveness” OR “cost-benefit” OR 
“cost-utility”. Our search identified eight studies. 
A 2008 systematic review identified four studies on the 
cost-effectiveness of glaucoma screening published before 
2005 and concluded that all these studies featured 
methodological weaknesses and outdated screening 
technology and treatments, providing insufficient evidence on 
which to base policy recommendations. The studies we 
identified published from 2005 onwards included studies in 
the UK, the USA, and Finland, which focused on screening 
solely for primary open angle glaucoma (POAG), the most 
prevalent type of glaucoma in these countries. These studies 
reported that population-based glaucoma screening 
programmes are not cost-effective in these high-income 
countries. The only cost-effectiveness study of glaucoma 
screening in an Asian population found that screening is 
highly cost-effective in India. However, a one-time decision 
analysis was used, which failed to capture the complexity of 
glaucoma progression in a temporally explicit fashion.
Added value of this study
The scenario of combined primary angle closure glaucoma 
(PACG) and POAG screening is likely to be cost-effective in the 
rural setting (incremental cost-effectiveness ratio US$1280, 
95% CI −58 to 7940; incremental cost-utility ratio $569, 95% CI 
17 to 4180) and dominates no screening in the urban setting. 
A total of 246 years (95% CI 63 to 628) of blindness would be 
avoided for every 100 000 rural residents screened and 1325 years 
(510 to 2828) for every 100 000 urban residents screened.
Implications of all the available evidence
Our finding that glaucoma screening is cost-effective in a large 
country like China could be of great importance to policy makers 
and programme planners. Previous conclusions that glaucoma 
screening is not cost-effective have been based on assumptions 
that apply more to high-resource settings—where most such 
research has been done—than low-income and middle-income 
countries such as China. This novel finding in China might result 
from a combination of lower screening costs and higher risk of 
eventual blindness in the absence of such programmes in the 
Chinese setting compared with high-income countries. It is also 
likely that the greater cost-effectiveness of screening for PACG, 
far more prevalent in China than in European-derived 
populations, plays an important role.
See Online for appendix
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encompassing five stages besides normal vision: PAC 
suspect, PAC, PACG without blindness, PACG­related 
unilateral blindness, and PACG­related bilateral 
blindness.18 For both PACG and POAG, the risk of 
progression from one state to the next was reduced by 
various types of treatment, with the amplitude of 
reduction based on available published data.
Glaucoma prevalence
Prevalence studies specific to China have typically reported 
separate prevalence for POAG and PACG. We reviewed 
population­based studies on glaucoma preva lence done 
among Chinese populations by searching PubMed, 
MEDLINE, and Embase for articles published in English 
appearing after the initiation of the ISGEO diagnostic 
criteria in 2002, using the following combined terms: 
“glaucoma” AND “prevalence” OR “epidemiology” AND 
“China” OR “Chinese”. We identified ten studies, among 
which seven (five in rural and two in urban settings, 
comprising a total of 22 070 participants) reported preva­
lence of PACG and eight (five rural and three urban, 
comprising 24 598 participants) reported prevalence of 
POAG (appendix). After appraising them using the 
frameworks of Boyle19 and Morris,20 prevalence data were 
quantitatively synthesised by means of a random­effects 
meta­analysis21  processed in R version 3.5.1 (appendix). 
Prevalence of each ISGEO stage of POAG and PACG 
among people aged 50 years or older was synthesised 
separately for rural and urban settings. Because of 
insufficient data, it was inappropriate to provide separate 
prevalence estimates for bilateral POAG blindness for 
rural and urban areas and so a single estimate was 
provided for both. We used data from a glaucoma 
screening programme of 27 144 participants in Wenzhou, 
China,6 that was carried out by a coauthor (YL) between 
March, 2014, and September, 2015, to estimate the propor­
tion of patients with POAG with mild disease as 36·8%, 
moderate disease as 35·9%, and severe disease as 27·3%.
Our meta­analysis of prevalence studies indicated that 
49% of people with PACG in rural areas and 74% of those 
in urban areas had been previously diagnosed and 
treated, compared with only 7% and 10% of people with 
POAG (appendix). Based on the assumption that the 
proportion of people with previously diagnosed POAG 
would differ by severity, we assumed that 1·8% of rural 
patients with mild POAG, 3·2% of those with moderate 
POAG, and 17·9% of those with severe POAG had 
been treated previously. The comparable figures in the 
urban setting were 2·6%, 4·9%, and 26·7%, respectively. 
The percentage of people with asymptomatic stages of 
PACG (ie, PAC and PAC suspect) being opportunistically 
diagnosed was assumed to be zero for both rural and 
urban settings.
Transition probabilities
All transitions from one health state to another take place 
in a 1­year cycle. Whenever possible, data on all relevant 
parameters were obtained from published studies or data 
sources specific to China, which we obtained by searching 
PubMed, MEDLINE, CNKI, and Embase for studies on 
glaucoma progression published in English or Chinese, 
using the following combined terms: “glaucoma” AND 
“incidence” OR “transition” OR “progression” AND 
“China” OR “Chinese”. However, few data are available on 
the transition probabilities from one stage to the next stage 
without treatment intervention for Chinese patients with 
glaucoma. Therefore, these transition probabilities were 
inferred from studies done in other Asian countries, those 
having Chinese or closely related populations (such as 
Mongolia) being preferred (appendix). If Asian data were 
not available, we used transition probabilities estimated 
from other regions. In studies where multi­year rather 
than 1­year glaucoma incidence was reported, the 1­year 
incidence was calculated using the formula r = −log(1 − p)/t, 
where r denotes the 1­year incidence and p represents the 
cumulative incidence over length of interval t.22 Transition 
probabilities between stages of glaucoma after medical 
treatments were also based on published studies done in 
Asian countries, such as Mongolia and Singapore, or from 
unpublished data sources.
Screening and intervention costs
Screening costs were calculated on the basis of the 
Wenzhou glaucoma screening programme (table 1).6 
These included costs for screening equipment and labour 
costs for medical personnel. All figures were collected in 
Chinese yuan but were converted into US dollars at 
an exchange rate of 6·79 yuan per dollar. The total cost 
per person for PACG screening was $2·52 (appendix) 
Treatment costs 
per person for the 
first year (US$)
Annual medication 
costs per person in 
follow-up years (US$)
Screening and examination costs*
Screening PACG 2·52 NA
Screening POAG 3·20 NA
Combined screening 3·20 NA
Full ophthalmological 
examination at a hospital
15·9 NA
Treatment costs
PAC suspect 105 1·77
PAC 105 1·77
PACG 600 10·6
Mild POAG 256 256
Moderate POAG 345 230
Severe POAG 345 230
Unilateral blindness 6380 1080
Bilateral blindness 8920 3600
Costs are given to 3 significant figures. NA=not applicable. PACG=PAC glaucoma. 
POAG=primary open angle glaucoma. PAC=primary angle closure. *Detailed 
calculations on screening costs can be found in the appendix.
Table 1: Screening cost and medical cost of treating glaucoma of 
different stages
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whereas the figure for POAG was slightly higher at $3·20 
due to the need for additional equipment.
In China, patients usually pay for medical service at 
hospitals, the cost of which might be partially reimbursed 
by medical insurance. We considered the societal costs of 
medical care, so specific reimbursement rates were not 
relevant. The costs we used are the amounts charged for 
medical care provided by the Affiliated Eye Hospital of 
Wenzhou Medical University—an urban, tertiary­level 
centre serving a population of 9 million. A proposed 
screening programme would reach out to local rural and 
urban communities, and participants who screen positive 
after preliminary examinations would be referred to 
local hospitals for further examination (see appendix for 
pathways for both organised screening and opportunistic 
case detection). Following such preliminary community 
screening, all people with suspected glaucoma were 
assumed to be referred to local hospitals for a definitive 
ophthalmic examination including gonioscopy, slit­lamp 
examination of the anterior and posterior segment, 
fundus photography (Canon CR­2 Digital Retinal Camera; 
Canon, Tokyo, Japan; NIDEK Non­Mydriatic AFC­330 
auto fundus cameras; NIDEK, Tokyo, Japan), and auto­
mated perimetry (Humphrey750i; Carl Zeiss Meditec, 
Dublin, CA, USA). Those diagnosed with glaucoma were 
assumed to receive routine clinical care appropriate for 
the severity of glaucoma. Medications were assumed to 
be prescribed to patients with mild POAG. Patients with 
severe or moderate POAG or PACG were assumed to be 
treated by trabeculectomy, followed by postoperative 
medications for 6 weeks. Among them, 20% were 
assumed to fail the surgery and need long­term topical 
medical therapy.23–26 Patients with PAC suspect or PAC 
were assumed to be treated by laser peripheral iridotomy 
with 10% of laser­treated patients also needing glaucoma 
mediation.27
The costs for the medications and surgeries (table 1) 
were obtained from the tertiary hospital mentioned 
above. These costs are controlled by the Chinese 
Government and vary little between institutions at the 
same level of the health­care system. The annual 
economic burden per bilaterally blind patient used in 
our model ($8920) consisted of 53·2% direct medical 
costs, 6·4% direct non­medical costs, and 40·4% indirect 
costs.28 The latter consists of loss of labour resources, 
loss of productivity among carers (usually family 
members), and modification costs. We assumed that the 
total cost for the initial year of bilateral blindness was 
$8920 and that blind patients incurred only indirect 
costs (ie, $3600) in subsequent years until death. 
Because people with unilateral blindness experience 
fewer productivity losses and require fewer care services 
compared with people with bilateral blindness, the 
indirect cost of unilateral blindness was assumed to be 
30% of that for bilateral blindness, leading to an estimate 
of $6380 for the initial year of unilateral blindness and 
$1080 in subsequent years.
Compliance
Compliance in community­level screening was estimated 
by synthesising compliance data reported in those 
previous prevalence studies that offered similar free 
ophthalmologic examinations in China. Our meta­
analysis showed that 86% of eligible adults from rural 
areas and 80% from urban areas participated in 
community screening (table 2). Compliance with referral 
to the base hospital for further testing among patients 
informed they had signs of glaucoma was assumed to 
be 19% and 57% among rural16 and urban6 residents, 
respectively. Compliance with topical medical therapy 
was assumed to be 75% and 60% in the urban39 and rural38 
settings. Acceptance of recommended trabeculectomy 
surgery among patients diagnosed with PACG was 91% 
and 80% in the urban36 and rural15,29,30,32 settings, 
respectively. Compliance with laser peripheral iridotomy 
was assumed to be 78%27 and 32%,37 respectively, among 
urban and rural patients diagnosed with either PAC or 
PAC suspect.
Screening sensitivity and specificity
Sensitivity (95·3%) and specificity (34·0%) of the 
proposed outreach community screening for PACG only 
are based on a screening examination including the 
van Herick test with a cutoff of no more than 40% anterior 
chamber depth for the limbal angle, as reported in a 
population­based screening programme in China.43 The 
sensitivity (64·0%) and specificity (95·0%) for optic 
nerve photographs are used in modelling the accuracy of 
POAG screening.44 In the combined screening scenario, 
the sensitivity (98·3%) and specificity (32·3%) in the 
detection of PACG are based on combined sensitivities 
and specificities of the van Herick test and optic nerve 
photography.
Utilities and quality-adjusted life-years
To calculate quality­adjusted life­years (QALYs), we 
estimated utilities for each glaucoma stage. Some early 
stages of glaucoma, such as PAC suspect and PAC, are 
asymptomatic, so the utilities for the three health states 
were assumed equal to the full utility of a person free from 
glaucoma. Utilities were assumed to be 0·80 for people 
with mild POAG, 0·75 for those with moderate POAG, 
and 0·71 for those with severe POAG.7 Following results 
in the Handan Eye Study,40 patients with PACG without 
blindness were assumed to have a utility value of 0·75, 
whereas patients with unilateral and bilateral blindness 
were assumed to have utility values of 0·47 and 0·26, 
respectively.41
Other parameters
We used the natural age­specific mortality rates reported 
by Zhang and Wei.45 Mortality rates were also allowed to 
depend on glaucoma severity with increased odds of 
mortality for people with mild and moderate POAG,46 
PACG without blindness,46 and unilateral and bilateral 
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blindness (table 2).47 Following the National Institute for 
Health and Care Excellence (NICE) recommendations,42 
both costs and health state utilities were discounted at 
3·5% per annum in the base­case analysis. In terms 
of cost­effectiveness threshold, WHO defines a health 
intervention as being very cost­effective if it costs less 
than the per­capita gross domestic product (GDP) for a 
given country and as cost­effective if it costs less than 
three times the per­capita GDP.48 The per­capita GDP 
stratified for China’s rural and urban areas was not 
directly available but were calculated to be $4010 and 
$10 800, respectively, inferred from the overall per­capita 
national GDP ($7950), urbanisation rate, and the urban–
rural ratio (2·72) of per­capita disposable income.49
Outcomes
Main outcomes were incremental cost­utility ratios 
(ICURs) and incremental cost­effectiveness ratios (ICERs), 
calculated as the difference in the total costs between the 
screened and unscreened cohorts, divided by the dif­
ference in the total QALYs between the two cohorts 
(ICURs) or by the years of blindness avoided between the 
two cohorts (ICERs). Differences were calculated as values 
for the screened cohort minus values for the unscreened 
cohort. Positive ICURs and ICERs show the incremental 
costs required for increasing 1 QALY or avoiding 1 year of 
blindness per person, respectively. Negative ICURs and 
ICERs (regarded as dominating) indicate that screening 
results in fewer costs while increasing QALYs or avoiding 
additional years of blindness than does no screening. 
A half­cycle correction50 was applied to both costs and 
benefits. Reporting of methods and results conform to the 
Consolidated Health Economic Evaluation Reporting 
Standards (appendix).51
Sensitivity analysis
To reflect the uncertainty around ICURs and ICERs, 
both one­way deterministic and simulated probabilistic 
sensitivity analyses were done. Differential discounting 
was used in the sensitivity analysis such that costs were 
discounted by 3·5% per annum and health state utilities 
by 1·5%.42 The 95% CIs from the meta­analyses of 
glaucoma prevalence were used as the upper and 
lower bounds of the one­way deterministic sensitivity 
analysis.52 A change of either 20% or 50% of the original 
values of the other parameters was used, depending 
on the uncertainty of the base­case parameters (appendix).53 
Additional sensitivity analyses were done by varying 
glaucoma­related mortality, indirect costs from blindness, 
and opportunistic detection rate of PAC and PAC 
suspect. Tornado diagrams were produced showing the 
five factors to which the ICURs were most sensitive. For 
the probabilistic sensitivity analysis, a beta distribution 
was assigned to prevalence and transition probabilities, a 
log­normal distribution to odds ratios, and a gamma 
distribution to cost param eters.54 The upper and lower 
bounds used in the one­way probabilistic sensitivity 
Values Source
Compliance with community screening
Rural setting 86% Liang et al,29 Qu et al,30 Zhong et al,31 
Song et al,32 Sun et al33
Urban setting 80% He et al,14 He et al,34 Wang et al35
Compliance with comprehensive hospital examination
Rural setting 18·9% Wang et al16
Urban setting 56·9% Liang et al6
Compliance with trabeculectomy among patients with PACG and moderate and severe POAG
Rural setting 80% Liang et al,29 Qu et al,30 Song et al,32 
Pan et al15
Urban setting 91% Sun et al36
Compliance with laser therapy among patients with PAC and PAC suspect
Rural setting 32% Thomas et al37
Urban setting 78% Jiang et al27
Compliance with medication
Rural setting 60% Li et al38
Urban setting 75% Lui et al39
Utilities
No disease 1·00 Assumption
Mild POAG 0·80 Burr et al7
Moderate POAG 0·75 Burr et al7
Severe POAG 0·71 Burr et al7
PAC suspect 1·00 Assumption
PAC 1·00 Assumption
PACG 0·75 Sun et al40
Unilateral blindness 0·47 Brown et al41
Bilateral blindness 0·26 Brown et al41
Discount rate for costs and benefits (base-case analysis) 3·5% NICE42
Discount rate for benefits (sensitivity analysis) 1·5% NICE42
Sensitivity at community screening
PACG only 95·3% Zhang et al43
POAG only and in combined screening 64·0% Maa et al44
PACG in combined screening 98·3% Zhang et al,43 Maa et al44
Specificity at community screening
PACG only 34·0% Zhang et al43
POAG only and in combined screening 95·0% Maa et al44
PACG in combined screening 32·3% Zhang et al,43 Maa et al44
Mortality rates by age group, years
50–54 0·364% Zhang and Wei45
55–59 0·518% Zhang and Wei45
60–64 0·854% Zhang and Wei45
65–69 1·421% Zhang and Wei45
70–74 3·149% Zhang and Wei45
75–79 4·861% Zhang and Wei45
80–84 8·932% Zhang and Wei45
Increased mortality risk for different groups, odds ratio
People with mild, moderate, or severe POAG 1·8 Xu et al46
People with PACG but not blindness 3·1 Xu et al46
People with unilateral or bilateral blindness 3·9 Li et al47
Values and sources are the same for both urban and rural settings unless otherwise specified. PACG=PAC glaucoma. 
POAG=primary open angle glaucoma. PAC=primary angle closure. NICE=National Institute for Health and Care 
Excellence. 
Table 2: Estimates for compliance, utility, mortality, and other parameters
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analysis were used to define the distribution parameters. 
Probabilistic uncertainty was evaluated by recalculating 
ICERs for 10 000 random draws from the probability 
distribution of each parameter.53,55 The percentile­based 
non­parametric bootstrap method56 was used to calculate 
the 95% CIs for the ICURs and ICERs.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
The cost­utility analysis shows that programmatic 
screening for PACG but not POAG dominated no 
screening in the urban setting (table 3). In the rural 
setting, screening for PACG required extra financial 
investment but was still likely to be cost­effective 
(ICUR $290, 95% CI −390 to 1840). POAG screening in 
the urban setting compared with no screening gained 
1 QALY at a cost of $9060 (95% CI 4700 to 20 400), 
satisfying the criterion for a highly cost­effective health 
intervention. However, POAG screening in rural areas 
yielded an ICUR of $15 000 (7020 to 50 500), which is 
approximately 3·7 times of rural GDP. When screening 
for both POAG and PACG simultaneously, as would 
usually be the case in practice, screening dominated no 
screening in the urban setting and the ICUR for the rural 
setting was $569 (17 to 4180), again suggesting that a 
screening programme is likely to be cost­effective in both 
settings.
Parallel to the cost­utility analysis, the cost­effectiveness 
analysis showed that screening for PACG alone resulted 
in fewer costs and decreased years of blindness than did 
no screening in the urban setting (table 3). In the rural 
setting, such screening would avoid 1 year of blindness at 
an ICER of $670 (95% CI −823 to 4570). Screening for 
POAG in rural areas avoided 1 year of blindness at a cost 
of $15 600 (6940 to 68 200), which was approximately 
3·9 times the rural per­capita GDP. By contrast, POAG 
screening in urban areas yielded an ICER of $7510 
(3860 to 22 000) per year of blindness avoided and was thus 
likely to be cost­effective. Finally, a scenario of combined 
PACG and POAG screening dominated no screening in 
the urban setting and was likely to be cost­effective 
(ICER $1280, 95% CI −58 to 7940) in the rural setting. 
With such a screening programme, over the 30­year time 
horizon investigated in the model an estimated 246 years 
(95% CI 63 to 628) of blindness would be avoided for 
every 100 000 rural residents screened and 1325 years 
(510 to 2828) avoided for every 100 000 urban residents 







100 000 people 
screened, $
Incremental QALYs 
(95% CI) per 
100 000 people 
screened
ICURs (95% CI), $ Years of 
blindness per 
person
Years of blindness 
avoided per 
100 000 people 
screened
ICERs (95% CI), $
Rural setting
PACG
No screening 386 16·23 ·· ·· ·· 0·18091 ·· ··
Screening 387 16·23 149 000 512 (172 to 1849) 290 (−390 to 1840) 0·17879 212 (72 to 702) 670 (−823 to 4570)
POAG
No screening 153 16·44 ·· ·· ·· 0·06795 ·· ··
Screening 157 16·44 456 000 30 (7 to 76) 15 000 (7020 to 50 500) 0·06766 29 (5 to 80) 15 600 (6940 to 68 200)
Combined
No screening 522 16·02 ·· ·· ·· 0·024608 ·· ··
Screening 525 16·03 313 000 551 (115 to 1398) 569 (17 to 4180) 0·024363 246 (63 to 628) 1280 (−58 to 7940)
Urban setting
PACG
No screening 347 16·20 ·· ·· ·· 0·015413 ·· ··
Screening 334 16·24 −1 288 000 3940 (1197 to 8032) Dominating 0·014281 1132 (343 to 2425) Dominating
POAG
No screening 200 16·37 ·· ·· ·· 0·08632 ·· ··
Screening 212 16·38 1 219 000 135 (41 to 298) 9060 (4700 to 20 400) 0·08469 162 (40 to 335) 7510 (3860 to 22 000)
Combined
No screening 533 15·93 ·· ·· ·· 0·23723 ·· ··
Screening 526 15·98 −701 000 4193 (1407 to 8563) Dominating 0·22398 1325 (510 to 2828) Dominating
Costs are given in US dollars. Costs, QALYs, and years of blindness are lifetime values per person, whereas incremental costs, incremental QALYs, ICURs, years of blindness avoided, and ICERs are calculated against the 
no screening scenario per 100 000 people screened. Negative ICURs and ICERs are regarded as dominating. QALY=quality-adjusted life-year. ICUR=incremental cost-utility ratio. ICER=incremental cost-effectiveness 
ratio. PACG=primary angle closure glaucoma. POAG=primary open angle glaucoma. 
Table 3: Base-case cost-utility and cost-effectiveness results from glaucoma screening compared with no screening for rural and urban settings
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shows that combined screening in the rural setting is cost­
effective for all age groups (appendix).
For the scenario of screening for PACG only and the 
combined strategy screening for both POAG and PACG, 
the base­case results were insensitive to uncertainty over 
a broad range of parameter values that we specified in the 
model, with all screening scenarios consistently dominant 
or within one­times per­capita GDP (figure). Threshold 
analysis showed that combined screening stopped being 
cost­effective if screening cost per person was more than 
$34·2 in rural areas (11 times the actual cost of the model 
screening programme used in our estimates) and more 
than $558 in urban areas (174 times the actual cost), based 
on a willingness­to­pay threshold of three­times per­
capita GDP. For POAG screening, varying the parameters 
caused the ICUR to exceed the cost­effectiveness 
threshold of three­times per­capita GDP for the rural 
setting but not the urban setting (figure). Model results 
were robust to several additional sensitivity analyses, 
varying glaucoma­related mortality, indirect costs from 
blindness, and the percentage of PAC and PAC suspect 
being opportunistically diagnosed (appendix).
Probabilistic sensitivity analysis showed that the base­
case ICUR and ICER were robust to randomly distributed 
parameters (appendix). PACG screening in rural areas 
dominated no screening in 18·9% of the simulations 
and did not dominate yet remained cost­effective in 
the remaining 81·1%. Likewise, in the urban setting, 
PACG screening dominated no screening in 89·3% of 
simulations and was cost­effective in the remaining 10·7%. 
Screening for POAG but not PACG was unlikely to be 
cost­effective in the rural setting because the ICUR 
exceeded the cost­effectiveness criterion of three­times 
per­capita GDP in 76·4% of simulations. By contrast, 
there was only 0·3% chance that screening in urban areas 
for POAG was not cost­effective. Finally, when both 
Figure: Deterministic one-way sensitivity analysis
Costs are given in US dollars. Analysis is done on the five parameters that caused the largest changes to the ICUR in each screening combination in different settings. The 
intervention was defined as cost-effective if it cost less than $12 030 in rural areas (per-capita GDP $4010) and less than $32 000 in urban areas (per-capita GDP $10 800). 
GDP=gross domestic product. ICUR=incremental cost-utility ratio. PAC=primary angle closure. PACG=PAC glaucoma. POAG=primary open angle glaucoma.
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POAG and PACG were simultaneously screened, 
screening rural and urban residents was cost­effective in 
99·9% and 100·0% of simulations, respectively.
In both rural and urban settings, more frequent 
screening avoided more years of blindness (table 4). In 
the base case, the best scenario was annual screening, 
which yielded the largest health benefits with required 
additional costs within the WHO very cost­effective 
threshold (table 4). When compliance with screening, 
laser, and medical treatments was assumed to be perfect, 
annual screening in rural areas was close to the cost­
effective threshold and screening every 2 years was the 
best strategy (table 4). By contrast, annual screening in 
urban areas might still be consistently cost­effective, 
even with perfect compliance.
Discussion
Our study suggests that combined screening for 
POAG and PACG in China is likely to be cost­effective, 
apparently due to the relatively low costs of screening, 
particularly labour costs, and the high risk of blindness 
in untreated cases, particularly those with PACG. Such 
screening in China is likely to fulfil WHO’s criteria57 for 
population screening: the natural history of glaucoma is 
adequately understood, early asymptomatic glaucoma 
stages are recognisable, screening is acceptable to the 
population, labour costs are low, and facilities for 
diagnosis and treatment are reasonably available.
We compared our results with previous studies. Our 
finding that a hypothetical screening for POAG (but not 
PACG) for individuals aged 50 years or older is not 
cost­effective in rural areas accords with studies on 
European­derived populations where POAG is by far 
the most prevalent form of glaucoma. For instance, the 
incremental cost of 1 QALY gained by a POAG screening 
programme in Finland was found to be $38 300, which 
fell below the cost­effectiveness threshold.9 However, 
due to uncertainty in the prevalence of glaucoma, the 
probabilistic sensitivity analysis of this result showed that 
screening might not be cost­effective in 29% of simulated 
cases. Screening for POAG in the UK resulted in an ICER 
above the threshold of £30 000 ($39 800) over a broad 
range of assumed POAG prevalences (1% to 10%).7 This 
result might have been due to a combination of higher 
screening costs and lower savings in a high­resource 
environment where POAG—the type less likely to lead to 
blindness—predominates and many patients would be 
detected in non­screening settings such as during routine 
glasses checks. In a more recent study8 on the worth 
of doing a randomised controlled trial on glaucoma 
screening in the UK, it was found to be unlikely to be 
worthwhile and resulted in an ICER that was three to 
four times the NICE recommended threshold. In the 
USA, routine patient­initiated ophthalmologic assess­
ments might be cost­effective ($46 000 per QALY) but 
the results were sensitive to assumptions.58 As a result 
of this evidence, multiple bodies of academics, policy 
makers, and programme planners, including the US 
Preventive Healthcare Task Force,59 the Royal College 
of Ophthal mologists,60 and the American Academy of 
Rural setting Urban setting Comparison 
screening 







Years of blindness 
avoided per 




100 000 people 
screened, $





Years of blindness 
avoided per 




100 000 people 
screened, $
ICERs, $
Imperfect compliance (base case)
One-off 0·24363 525·0 ·· ·· ·· 0·22398 526·1 ·· ·· ·· ··
10 years 0·23870 530·8 493 585 000 1190 0·20776 528·3 1622 224 000 138 One-off
5 years 0·23280 538·5 590 769 000 1300 0·19212 531·5 1564 316 000 202 10 years
3 years 0·22601 547·8 679 925 000 1360 0·17944 537·4 1268 594 000 469 5 years
2 years 0·21881 558·1 720 1 035 000 1440 0·17006 545·8 938 838 000 894 3 years
1 year 0·20317 584·5 1564 2 637 000 1690 0·15774 570·5 1232 2 471 000 2010 2 years
Assumption of perfect compliance
One-off 0·21220 509·1 ·· ·· ·· 0·20112 510·2 ·· ·· ·· ··
10 years 0·18143 504·5 3077 457 000 149 0·17163 511·8 2949 156 000 53 One-off
5 years 0·16896 516·2 1247 1 165 000 934 0·15829 525·4 1334 1 359 000 1020 10 years
3 years 0·16373 531·3 523 1 512 000 2890 0·15237 541·5 592 1 609 000 2720 5 years
2 years 0·16110 546·0 263 1 465 000 5570 0·14930 556·6 307 1 512 000 4920 3 years
1 year 0·15848 578·0 262 3 201 000 12 000 0·14613 588·7 317 3 209 000 10 100 2 years
Costs are given in US dollars. Years of blindness and costs are lifetime values per person screened whereas years of blindness avoided, incremental costs, and ICERs are calculated per 100 000 people screened 
against the previous screening interval scenario. 95% CIs for ICERs are presented in the appendix (p 21). ICER=incremental cost-effectiveness ratio.
Table 4: Cost-effectiveness of combined screening with varied compliance levels and screening intervals
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Ophthalmology,61 have concluded either that glaucoma 
screening is not cost­effective or that evidence is 
insufficient to conclude on its cost­effectiveness. None of 
these policy statements has recommended glaucoma 
screening in the general population. Regarding glaucoma 
screening in lower­income and middle­income countries, 
a population­based screening programme has been 
shown to be cost­effective in India.13 However, this 
analysis used a static decision­analytic model that was 
primarily concerned with one­time treatment costs and 
thus it was not possible to consider lifetime costs, nor the 
transitions among different glaucomatous states, as 
rigorously as in the present study.
Our finding in a careful and well informed analysis that 
glaucoma screening is cost­effective in a large country like 
China is of potentially great importance to policy makers 
and programme planners. The published literature is in 
wide agreement that glaucoma screening is generally 
not cost­effective,7–9 but this is based on assumptions 
(eg, labour costs of screening are high, risk of blindness 
without screening is only moderate due to a reasonably 
accessible health­care system) that apply far better in high­
resource settings than low­income and middle­income 
countries such as China, where around 80% of the global 
burden of glaucoma blindness falls. Our article challenges 
this by looking carefully at a well documented screening 
programme in China, complemented by the fairly 
complete literature on glaucoma epidemiology that exists 
in China. We feel this novel finding in China might result 
from a combination of lower screening costs and higher 
risk of eventual blindness in the absence of such 
programmes in the Chinese setting compared with high­
income countries. It is also likely that the greater cost­
effectiveness of screening for PACG, which is far more 
prevalent in China than in European­derived populations, 
plays an important role.
Thus, results from our models are more likely to be 
applicable where labour costs are lower and risk of 
blindness in untreated people is especially high—eg, in 
low­income and middle­income countries, and especially 
those settings where highly blinding forms of glaucoma 
(PACG in east Asia and POAG in African­derived 
populations in sub­Saharan Africa and the Caribbean) 
are prevalent. Regarding the necessity of expensive 
technology for successful screening, which might present 
a barrier in such settings, we deliberately omitted 
consideration of costly approaches such as visual field 
analysers, gonioscopy lenses, and nerve fibre layer 
analysis to posit a screening model with broader appli­
cability. The approaches modelled here are likely to be 
particularly relevant in Asia, where it is estimated that 
61% of people living with glaucoma globally reside, and 
where cost­effectiveness of glaucoma screening has not 
been widely examined.1
Due to low expected compliance in China with hospital 
referrals from screening and with medical and laser 
therapies, we found in both rural and urban settings that 
each additional screening had the potential to identify 
additional people with early­stage glaucoma, and that 
more frequent, annual screening was the best strategy. 
However, when adherence was assumed to be perfect—
an unlikely assumption in view of the extensive 
literature—annual screening was unnecessary and 
screening every 2 years became the optimal strategy. With 
inadequate knowledge of glaucoma, patients and doctors 
in China generally perceive no need for comprehensive 
examinations to detect asymptomatic disease.62 Available 
evidence suggests that offering free examinations can 
improve acceptance of comprehensive examinations 
among asymptomatic patients in rural China.63 Full 
coverage of such examinations under the national health 
insurance system could assist with opportunistic, clinic­
based case detection of glaucoma. However, supporting 
broad­based population screening would require a 
substantial financial commitment from the government, 
which further research in this area might help to promote.
Our study has various strengths. To our knowledge, it 
is the first to analyse the cost­effectiveness of glaucoma 
screening in a low­income or middle­income country on 
the basis of a temporally explicit Markov model. Costs of 
screening and treatment were adopted from actual 
screening programmes and health­care facilities in 
China. Our analysis employed prevalence and transition 
probability estimates based on the globally recognised 
ISGEO classification system and a careful review of the 
published literature. Our policy­relevant conclusions 
about the cost­effectiveness of glaucoma screening differ 
substantially from much of the existing literature, 
especially studies in high­resource countries, due to 
China’s unique characteristics, including relatively low 
screening costs and high probability of eye damage 
among unscreened persons, especially those with PACG.
A limitation of our study is that gaps in the existing 
literature required us to base some transition probabilities 
among health states in our Markov model on non­
Chinese data, leading to potential inaccuracies. Also, our 
analysis was not informed by prospective data from a 
randomised controlled trial. The use of the WHO cost­
effectiveness threshold for cost per year of blindness 
avoided is consistent with previous studies, but it is 
unclear whether the WHO thresholds are generalisable to 
disease­specific outcomes or QALYs.9 The rural–urban 
comparison was done for illustrative purposes because 
the rural and urban GDP were calculated from overall 
GDP adjusted for income disparity in both settings. 
Although screening in urban areas might seem more 
cost­effective than in rural areas, such screening should 
be offered to both rural and urban residents for equity 
reasons. Further, we did not stratify our analyses by sex. 
Neither was the cost­effectiveness of different screening 
strategies compared in our study. In the absence of 
Chinese data on compliance with glaucoma medications, 
we based our estimates on studies of other chronic 
conditions, such as diabetic retinopathy and hypertension. 
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Because adherence to hospital examinations and medical 
and laser therapies is low in China,6,16,64 there is substantial 
room for future studies to investigate the potential effects 
on adherence of various behavioural, economic, and 
educational interventions.
In conclusion, combined population screening for 
POAG and PACG among Chinese adults aged 50 years or 
older is likely to be cost­effective in both rural and urban 
settings. Our findings were insensitive to variations 
across a wide range of input parameters and were robust 
in the probabilistic sensitivity analyses. These results are 
more likely to be applicable in other settings where labour 
costs are low, highly blinding forms of glaucoma are 
prevalent, and opportunistic detection rates are low. A 
sustainable model might be for Chinese hospitals to offer 
free glaucoma examinations to residents living in local 
villages and communities that, under present funding 
arrange ments, could increase the number of glaucoma 
inpatients and in turn increase their profits. Future 
studies should investigate the effectiveness of 
interventions among screened people to improve their 
compliance with hospital examination and acceptance of 
definitive care.
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